Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30251% above fair value
$4.65−0.13 (-2.72%)
Close on Nov 12, 2026Market cap $64.72MP/E –Yield –
Champions Oncology operating margin
Operating margin is operating income as a percentage of revenue.
Champions Oncology's operating margin for the twelve months ending Jul 31, 2026 was -1.7%. For fiscal 2026 it was -1.9%, against 8.0% the year before. The highest annual figure on record is 9.3% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -1.9% | −9.9 |
| FY2025 | Apr 30, 2025 | 8.0% | +22.7 |
| FY2024 | Apr 30, 2024 | -14.7% | −4.9 |
| FY2023 | Apr 30, 2023 | -9.8% | −11.0 |
| FY2022 | Apr 30, 2022 | 1.2% | +0.3 |
| FY2021 | Apr 30, 2021 | 0.9% | +6.9 |
| FY2020 | Apr 30, 2020 | -6.0% | −15.3 |
| FY2019 | Apr 30, 2019 | 9.3% | +16.0 |
| FY2018 | Apr 30, 2018 | -6.7% | +37.5 |
| FY2017 | Apr 30, 2017 | -44.2% | +48.1 |
| FY2016 | Apr 30, 2016 | -92.3% | +57.1 |
| FY2015 | Apr 30, 2015 | -149.4% | −95.2 |
| FY2014 | Apr 30, 2014 | -54.2% | +20.5 |
| FY2013 | Apr 30, 2013 | -74.7% | +52.1 |
| FY2012 | Apr 30, 2012 | -126.8% | −50.7 |
| FY2011 | Apr 30, 2011 | -76.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -2.7% | +1.1 |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -3.8% | +12.5 |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -1.7% | −28.1 |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | 1.2% | −4.2 |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | -3.8% | −13.2 |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | -16.2% | −14.3 |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | 26.4% | +47.8 |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | 5.4% | +22.3 |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | 9.5% | +29.8 |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -1.9% | +17.4 |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -21.4% | −2.2 |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -16.9% | −16.9 |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -20.3% | −18.3 |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -19.3% | −16.9 |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -19.2% | −25.5 |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | 0.0% | −2.2 |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -2.1% | −0.5 |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | -2.4% | +3.7 |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | 6.3% | −2.8 |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | 2.2% | +2.2 |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -1.6% | −1.8 |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -6.1% | +17.1 |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | 9.1% | +4.3 |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | 0.1% | −3.7 |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | 0.3% | +9.4 |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | -23.2% | −21.7 |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | 4.8% | +10.6 |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | 3.8% | −0.3 |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | -9.1% | −16.8 |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | -1.5% | +10.7 |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | -5.8% | −4.4 |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | 4.1% | +5.5 |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | 7.7% | +20.0 |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | -12.2% | +52.1 |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | -1.3% | +38.0 |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | -1.3% | +9.7 |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | -12.3% | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | -64.2% | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | -39.3% | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | -11.1% | – |
See a number that looks wrong?